Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC Capital upgrades Antofagasta to 'sector perform'

(Sharecast News) - RBC Capital Markets upgraded Antofagasta on Thursday to 'sector perform' from 'underperform' but cut the price target to 1,700p from 1,800p. The bank said copper will continue to be kicked around by trade war escalations and de-escalations.

"Our concerns on possible downside scenarios have been tempered by price sensitive demand coming out of China," it said.

"However, on the flip side there will be lasting economic damage caused by the uncertainty that likely removes any material upside over the next twelve months."

It noted that since 25 March, Antofagasta shares and the LME copper price have fallen 20.5% and 9.3%, respectively.

"We are more comfortable on the risk profile at these levels and upgrade to sector perform," RBC said.

At 1230 BST, the shares were down 1.3% at 1,534.50p. They are trading ex-dividend.

Share this article

Related Sharecast Articles

BioNTech to invest up to £1bn in UK R&D expansion
(Sharecast News) - BioNTech announced on Tuesday that it will invest up to £1bn over the next decade to expand its research and development footprint in the UK, backed by a government grant of up to £129m.
Image Scan warns on profits, shares slump
(Sharecast News) - Shares in Image Scan tumbled on Tuesday, after the X-ray screening specialist warned on profits following a "disappointing" first half.
Mosman Oil & Gas in talks to sell Billy Goat rights
(Sharecast News) - Mosman Oil and Gas said on Tuesday that it has been in talks with a local helium business interested in buying the first well and associated contractual rights of the Billy Goat area of mutual interest (AMI) lease at its Vecta Project in Colorado.
RBC Capital ups price target on Hikma
(Sharecast News) - RBC Capital Markets has upped both forecasts and its price target for blue chip generics specialist Hikma Pharmaceuticals.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.